| abstract |
The present invention provides methods and compositions for treating cancer using a combination of a CYP17 inhibitor and an additional therapeutic agent that modulates the PBK / Akt / mTOR pathway. In one aspect, the present invention provides a method for the treatment of a disorder in a human subject. In some embodiments, the disorder is a neoplastic disorder. In some embodiments, the neoplastic disorder is cancer. In some embodiments, the method comprises administering to the subject a 17a-hydroxylase / C17,20-lyase inhibitor (CYP17 inhibitor) and an additional therapeutic agent, wherein the additional therapeutic agent is PBK. Inhibitors and / or mTOR inhibitors. [Selection figure] None |